Terms: = Leukemia AND PCM1, Q15154, PTC4, ENSG00000078674, 5108 AND Treatment
17 results:
1. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract] [Full Text] [Related]
2. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
[TBL] [Abstract] [Full Text] [Related]
4. pcm1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
[TBL] [Abstract] [Full Text] [Related]
5. Myeloid Neoplasm with pcm1-PDGFRB Transcript Responded to Low-Dose Imatinib: One Case Report with Literature Review.
Wang Z; Wan L; Lin D; Li CW; Tian Z; Mi YC
Acta Haematol; 2022; 145(5):560-565. PubMed ID: 35340014
[TBL] [Abstract] [Full Text] [Related]
6. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract] [Full Text] [Related]
7. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with pcm1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract] [Full Text] [Related]
8. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract] [Full Text] [Related]
9. RNA Sequencing Analysis for the Identification of a pcm1/PDGFRB Fusion Gene Responsive to Imatinib.
Such E; Liquori A; Mora E; Marco-Ayala J; Avetisyan G; Regadera A; Ibañez F; Panadero J; Senent L; Llop M; Díaz A; Vicente A; Luna I; Ibáñez M; Barragán E; Sanz MA; Sanz G; Communidad Valenciana ; Cervera J
Acta Haematol; 2019; 142(2):92-97. PubMed ID: 31085913
[TBL] [Abstract] [Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract] [Full Text] [Related]
11. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
[TBL] [Abstract] [Full Text] [Related]
12. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with pcm1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
[TBL] [Abstract] [Full Text] [Related]
13. [Haploidentical nonmyeloablative allogeneic peripheral blood stem cell transplantation for treatment of refractory or relapsed leukemia: long-term follow-up].
Dong Z; Hu KX; Yu CL; Qiao JH; Sun QY; Ai HS; Guo M
Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):217-20. PubMed ID: 23683419
[TBL] [Abstract] [Full Text] [Related]
14. t(8;9)(p22;p24)/pcm1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract] [Full Text] [Related]
15. Hematologic adverse events associated with temozolomide.
Villano JL; Letarte N; Yu JM; Abdur S; Bressler LR
Cancer Chemother Pharmacol; 2012 Jan; 69(1):107-13. PubMed ID: 21614470
[TBL] [Abstract] [Full Text] [Related]
16. pcm1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract] [Full Text] [Related]
17. [The expression of CD19 in 210 cases of childhood acute leukemia and its significance].
Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
Zhonghua Er Ke Za Zhi; 2004 Mar; 42(3):188-91. PubMed ID: 15144712
[TBL] [Abstract] [Full Text] [Related]